Circulating activated protein C is reduced in young survivors of myocardial infarction and inversely correlates with the severity of coronary lesions

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 7, 2006, Pages 1530-1536

  Zorio, E ^a   Navarro, S ^a   Medina, P ^a   Estelles A ^a   Osa, A ^a   Rueda, J ^a   Cubillo, P ^a   Aznar, J ^a   España, Francisco ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Activated protein C; Inflammation; Myocardial infarction; Risk factors; Stenosis score

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ALPHA 1 ANTITRYPSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROTHROMBIN; TICLOPIDINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANGIOCARDIOGRAPHY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL;

ADULT; AGE FACTORS; CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PROTEIN C; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SURVIVORS;

EID: 33745257029     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01996.x     Document Type: Article

References (34)

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary syndromes. N Engl J Med 1992; 326: 242-50.
2. Esmon CT. The endothelial cell protein C receptor. Thromb Haemost 2000; 83: 639-43.
3. Dahlbäck B, Carlsson M, Svenson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
4. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia. Pathogenesis, clinical syndromes and management. Blood 1996; 87: 3531-44.
5. Bertina RM. Molecular risk factors for thrombosis. Thromb Haemost 1999; 82: 601-9.
6. España F, Vayá A, Mira Y, Medina P, Estellés A, Villa P, Falcó C, Aznar J. Low level of circulating activated protein C is a risk factor for venous thromboembolism. Thromb Haemost 2001; 86: 1368-73.
7. Snow TR, Deal MT, Dickey DT, Esmon CT. Protein C activation following coronary artery occlusion in the in situ porcine heart. Circulation 1991; 84: 293-9.
8. Arnaud E, Lafay M, Gaussem P, Picard V, Jandrot-Prrus M, Aiach M, Rendu F. An autoantibody directed against human thrombin anion-binding exosite in a patient with arterial thrombosis: Effects on platelets, endothelial cells, and protein C activation. Blood 1994; 84: 1843-50.
9. Zivelin A, Gitel S, Griffin JH, Xu X, Fernandez JA, Martinowitz U, Cohen Y, Halkin H, Seligsohn U, Inbal A. Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C. Blood 1999; 94: 895-901.
10. Kiechl S, Muigg A, Santer P, Mitterer M, Egger G, Oberhollenzer M, Oberhollenzer F, Mayr A, Gasperi A, Poewe W, Willeit J. Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. Circulation 1999; 99: 614-9.
11. Sakata T, Kario K, Katayama Y, Matsuyama T, Kato H, Miyata T. Analysis of 45 episodes of arterial occlusive disease in Japanese patients with congenital protein C deficiency. Thromb Res 1999; 94: 69-78.
12. Tiong IY, Alkotob ML, Ghaffari S. Protein C deficiency manifesting as an acute myocardial infarction and ischaemic stroke. Heart 2003; 89: E7.
13. Ireland H, Kunz G, Kyrialkulis K, Stubbs PJ, Lane DA. Thrombomodulin gene mutations associated with myocardial infarction. Circulation 1997; 96: 15-8.
14. Biguzzi E, Merati G, Liaw PC, Bucciarelli P, Oganesyan N, Qu D, Gu JM, Fetiveau R, Esmon CT, Mannucci PM, Faioni EM. A 23 bp insertion in the endothelial protein C receptor (EPCR) gene impairs EPCR function. Thromb Haemost 2001; 86: 945-8.
15. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-69.
16. Sullivan DR, Marwick TH, Freedman SB. A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. Am Heart J 1990; 119: 1262-7.
17. España F, Zuazu I, Vicente V, Estellés A, Marco P, Aznar J. Quantification of circulating activated protein C in human plasma by immunoassays. Enzyme levels are proportional to total protein C levels. Thromb Haemost 1996; 75: 56-61.
18. Díez N, Montes R, Alonso A, Medina P, Navarro S, España F, Hermida J. Association of increased fibrinogen concentration with impaired activation of anticoagulant protein C. J Thromb Haemost 2006; 4: 398-402.
19. Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood 1992; 79: 2340-8.
20. España F, Vicente V, Tabernero D, Scharrer I, Griffin JH. Determination of plasma protein C inhibitor and of two activated protein C-inhibitor complexes in normals and in patients with intravascular coagulation and thrombotic disease. Thromb Res 1990; 59: 593-608.
21. Hendl S, España F, Aznar J, Estellés A, Gilabert J, Griffin JH. Functional and immunological determination of protein C by immunosorbent assays. Rev Iberoamer Tromb Hemost 1991; 4: 16-20.
22. España F, Hendl S, Gilabert J, Estellés A, Aznar J. Evaluation of two functional assays for the measurement of protein C inhibitor/plasminogen activator inhibitor-3 (PCI/PAI-3) activity. Thromb Res 1993; 70: 375-84.
23. Vossen CY, Hasstedt SJ, Rosendaal FR, Callas PW, Bauer KA, Broze GJ, Hoogendoorn H, Long GL, Scott BT, Bovill EG. Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C-deficient family. J Thromb Haemost 2004; 2: 242-7.
24. Fernández JA, Gruber A, Heeb MJ, Griffin JH. Protein C pathway impairment in nonsymptomatic cigarette smokers. Blood Cells Mol Dis 2002; 29: 73-82.
25. Li YH, Chen JH, Tsai WC, Chao TH, Guo HR, Tsai LM, Wu HL, Shi GY. Synergistic effect of thrombomodulin promoter -33G/A polymorphism and smoking on the onset of acute myocardial infarction. Thromb Haemost 2002; 87: 86-91.
26. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296: 1880-2.
27. Li W, Zheng X, Gu J, Hunter J, Ferrell GL, Lupu F, Esmon NL, Esmon CT. Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. J Thromb Haemost 2005; 3: 1351-9.
28. Joyce DE, Grinnell BW. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-κ B. Crit Care Med 2002; 30: S288-93.
29. Petaja J, Pesonen E, Fernandez JA, Griffin JH, Repo H, Jansson SF, Vento AE, Ramo OJ. Activated protein C and inflammation in human myocardium after heart surgery. Am J Hematol 2001; 67: 210-2.
30. Laszik ZG, Zhou XJ, Ferrell GL, Silva FG, Esmon CT. Down-regulation of endothelial expression of endothelial cell protein C receptor and thrombomodulin in coronary atherosclerosis. Am J Pathol 2001; 159: 797-802.
31. Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernández JA. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 1999; 103: 210-27.
32. Lentz SR, Fernández JA, Griffin JH, Piegors DJ, Erger RA, Malinow MR, Heistad DD. Impaired anticoagulant response to infusion of thrombin in atherosclerotic monkeys associated with acquired defects in the protein C system. Arterioscler Thromb Vasc Biol 1999; 19: 1744-50.
33. Lentz SR, Miller Jr FJ, Piegors DJ, Erger RA, Fernández JA, Griffin JH, Heistad DD. Anticoagulant responses to thrombin are enhanced during regression of atherosclerosis in monkeys. Circulation 2002; 106: 842-6.
34. Montes R, Hurtado V, Alonso A, Foco L, Zonzin P, Mannucci PM, Hermida J. Autoantibodies against the endothelial receptor of protein C are associated with acute myocardial infarction in young women. J Thromb Haemost 2005; 3: 1454-8.